




# PHARMACEUTICAL 2023



# Nuvalent Inc.

## Rank 14 of 446



## Nuvalent Inc.

### Rank 14 of 446

The relative strengths and weaknesses of Nuvalent Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Nuvalent Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 76% points. The greatest weakness of Nuvalent Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 15% points.

The company's Economic Capital Ratio, given in the ranking table, is 285%, being 241% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	477,991
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,481
Liabilities, Non-Current	0
Other Assets	4,468
Other Compr. Net Income	-266
Other Expenses	0
Other Liabilities	0
Other Net Income	4,254
Other Revenues	0
Property and Equipment	0
Research and Development	63,731
Selling, General and Administrative Expense	22,377

Output Variable	Value in 1000 USD
Assets	482,459
Liabilities	19,481
Expenses	86,108
Revenues	0
Stockholders Equity	462,978
Net Income	-81,854
Comprehensive Net Income	-81,987
Economic Capital Ratio	285%